930 results on '"Palomaki, Glenn E."'
Search Results
2. Preeclampsia at delivery is associated with lower serum vitamin D and higher antiangiogenic factors: a case control study
3. Use of Maternal Race and Weight Provides Equitable Performance in Serum Screening for Open Neural Tube Defects.
4. Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis
5. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG)
6. DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG)
7. Sequencing Cell-Free DNA in the Maternal Circulation to Screen for Down Syndrome, Other Common Trisomies, and Selected Genetic Disorders
8. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency
9. Adjusting antimüllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome
10. Levels of angiogenic markers in second-trimester maternal serum from in vitro fertilization pregnancies with oocyte donation
11. Assessment of laboratories offering cell-free (cf) DNA screening for Down syndrome: results of the 2018 College of American Pathology External Educational Exercises
12. Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)
13. TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches.
14. TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches
15. Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia
16. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing
17. Cell-free DNA-based prenatal screening via rolling circle amplification: Identifying and resolving analytic issues
18. Sequencing Cell-Free DNA in the Maternal Circulation to Screen for Down Syndrome, Other Common Trisomies, and Selected Genetic Disorders
19. Sequencing Cell Free DNA in the Maternal Circulation to Screen for Down Syndrome and Other Common Aneuploidies
20. Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population
21. sj-doc-1-msc-10.1177_09691413231173315 - Supplemental material for Cell-free DNA-based prenatal screening via rolling circle amplification: Identifying and resolving analytic issues
22. Use of first or second trimester serum markers, or both, to predict preeclampsia
23. Assessment of a Simplified Cell-Free DNA Method for Prenatal Down Syndrome Screening
24. TSH and FT4 Reference Intervals in Pregnancy: A Systematic Review and Individual Participant Data Meta-Analysis
25. An Educational Assessment of Evidence Used for Variant Classification
26. Additional file 1 of Preeclampsia at delivery is associated with lower serum vitamin D and higher antiangiogenic factors: a case control study
27. Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA
28. Evaluation of Patient Education Materials: The Example of Circulating cell free DNA Testing for Aneuploidy
29. Prenatal serum screening markers may not require adjustment in former smokers
30. Prenatal serum screening for Down syndrome and neural tube defects in the United States: Changes in utilization patterns from 2012 to 2020
31. Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures
32. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia
33. Surveillance of SARS-CoV-2 Antibodies in Early 2020 among Rhode Island Pregnancies.
34. Sequencing Cell Free DNA in the Maternal Circulation to Screen for Down Syndrome and Other Common Aneuploidies
35. “Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes
36. Association between 9p21 genomic markers and heart disease
37. Implications of High Free Thyroxine (FT4) Concentrations in Euthyroid Pregnancies: The FaSTER Trial
38. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome
39. Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women
40. A New Era in Noninvasive Prenatal Testing
41. Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study
42. First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study
43. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure
44. The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction
45. International Society for Prenatal Diagnosis Position Statement: cell free (cf) DNA screening for Down syndrome in multiple pregnancies
46. Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: a-Fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen
47. Comparative Effectiveness Review: Prostate Cancer Antigen 3 Testing for the Diagnosis and Management of Prostate Cancer
48. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies
49. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma
50. Circulating angiogenic proteins in trisomy 13
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.